Publications by authors named "S M Bhavnani"
Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data.
Antimicrob Agents Chemother
November 2024
Article Synopsis
- Sulbactam-durlobactam is a newly approved combination drug for treating specific types of pneumonia in adults, using data from multiple clinical studies to assess its pharmacokinetics.
- A complex four-compartment model was created to understand how the drug behaves in the body, factoring in both kidney and non-kidney clearance methods.
- Key findings showed that factors like body weight and renal function impact drug clearance, with the model being suitable for predicting how the drug performs in different patient populations.
Article Synopsis
- Despite advancements in emergency response, mortality rates from sudden cardiac arrest remain high due to gaps in bystander intervention and disparities in access to care.
- Recent innovations like machine learning algorithms show promise in identifying at-risk individuals and recognizing emergencies but need to be integrated into public health strategies.
- The authors suggest a system that combines data-driven technology with equitable public health approaches to enhance outcomes for sudden cardiac arrest.
Background: Antibiotic treatment for complicated urinary tract infections (cUTI)/acute pyelonephritis (AP) is often followed by recurrent bacteriuria in the absence of clinical symptoms. To understand factors predictive of clinical and microbiologic outcomes in patients with cUTI/AP, multivariable analyses were undertaken using pooled data from a global, phase 3 cUTI study.
Methods: Using data from 366 tebipenem pivoxil hydrobromide- and 378 ertapenem-treated patients from the Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) infected with Enterobacterales uropathogens, multivariable analyses for dichotomous efficacy endpoints were performed using logistic regression and pharmacokinetic-pharmacodynamic relationships were evaluated.
During pregnancy, two fetomaternal interfaces, the placenta-decidua basalis and the fetal membrane-decidua parietals, allow for fetal growth and maturation and fetal-maternal crosstalk, and protect the fetus from infectious and inflammatory signaling that could lead to adverse pregnancy outcomes. While the placenta has been studied extensively, the fetal membranes have been understudied, even though they play critical roles in pregnancy maintenance and the initiation of term or preterm parturition. Fetal membrane dysfunction has been associated with spontaneous preterm birth (PTB, < 37 weeks gestation) and preterm prelabor rupture of the membranes (PPROM), which is a disease of the fetal membranes.
View Article and Find Full Text PDF